Central neuromodulation provides a solution to years of suffering in anxiety or depression, among many other pathologies.
Dr. Beatrice Alemany and her team at Affidea Medicentro Leganés use repetitive Transcranial Magnetic Stimulation (rTMS) and direct Transcranial Electrical Stimulation (tDCS) techniques for the treatment of psychiatric pathologies, such as anxiety, depression and certain addictions.
They are non-invasive techniques, which can also be used in the treatment of pain, fibromyalgia, mild-moderate cognitive impairment and post-stroke sequelae. Recently, its efficacy in the treatment of post-ICD sequelae has been demonstrated.
Madrid, January 16, 2023 -. Dr. Beatriz Alemany and her team at Affidea Medicentro Leganés use repetitive Transcranial Magnetic Stimulation (rTMS) and direct Transcranial Electrical Stimulation (tDCS) techniques for the treatment of psychiatric pathologies, such as anxiety, depression, post-traumatic stress syndrome, mild/moderate cognitive impairment, fibromyalgia and post-COVID syndrome sequelae.
Both are non-invasive and painless neuromodulation techniques used to excite and depolarize neurons in the brain and peripheral nervous system, using electromagnetic induction, by means of weak electrical currents induced in the tissue using magnetic fields (rTMS) or direct electrical current (tDCS). Both are based on the principle of central neuromodulation, capable of modifying neuronal excitability by means of electromagnetic principles.
One of the most important advantages is that these are non-pharmacological therapies, applied in both drug-resistant and non-drug resistant patients. These methods are ambulatory, painless, safe and their efficacy has been approved by several international organizations.
In order to improve the quality of life and reduce or eliminate the patient's suffering, the Affidea Medicentro Leganés team, a transdisciplinary team made up of psychiatrists, neurologists, and neurophysiologists together with a wide range of specialties that offer their support in each situation, is highly qualified to carry out the personalized treatment and follow-up of each patient.
Dr. Beatriz Alemany points out that "patients with high suffering, such as those suffering from depression or chronic anxiety, often socially misunderstood and therapeutically limited, radically change their lives, they feel like doing projects, physical exercise, going out and socializing again without having the continuous and enslaving need to make sure they carry an anxiolytic 'just in case'".
The duration of the treatment can vary from 5 minutes to about 40 minutes, "depending on what we want to treat, how we are going to treat it, after reviewing the latest publications on the pathology of each patient and developing an exclusive protocol for each one of them," explains Dr. Alemany.
The effectiveness of the treatment has been demonstrated in multiple pathologies. Currently, Affidea Medicentro treats only those pathologies that have been approved for efficacy and safety at an international level, both by the American (FDA) and European (EMA) Medicines Agencies.
Alemany confesses that "the moment in which a patient with fibromyalgia, depression, anxiety, post-traumatic stress syndrome, enters the door of the office is a moment charged with intensity. When a patient is sick in body, he or she is often sick in soul (or so my grandfather used to say, since we are millennials). These people often have been through multiple consultations, have been polymedicated, feel misunderstood and often have lost all hope that their situation can change. When you explain the treatment to them, many of them are really shocked. I think most of them don't believe a word of it at first. But when you see how they improve day after day, when you see how their facial expression, their desire to be and to do are transformed, that is when you realize that every effort for each one of them is little to thank for knowing that this person has started a new life".
Written by Dr. Beatriz Alemany
About Affidea Spain
Affidea España (www.affidea.es) is a leading medical provider of diagnostic imaging, nuclear medicine and outpatient medical specialties, with 43 centers nationwide. Affidea España performs more than 900,000 diagnostic imaging examinations each year, offering a medical service of excellence at the forefront of patient care. The company works with more than 1,100 professionals. Affidea Spain is recognized for its focus on patient safety, having all its centers accredited for excellence in nuclear medicine by the European Union of Medical Specialties (UEMS) and the European Board of Nuclear Medicine (EBNM), as well as all centers with CT accredited by the European Society of Radiology in Europe, on the EuroSafe Imaging Wall of Stars.
Media contact: Elena Ayuso - 656 321 906 - elena.ayuso@affidea.com - Laura Terzagui - 650 446 543 laura.terzagui@affidea.com - ES_prensa@affidea.com
About Affidea Group
Affidea Group (www.affidea.com) is Europe's largest provider of advanced diagnostic imaging, outpatient and cancer treatment services. Founded in 1991, the company operates 329 medical centers in 15 countries and provides advanced diagnostic, outpatient and cancer treatment services to more than 12 million patients a year. Thanks to its high standards in patient safety, Affidea is the most awarded provider of medical imaging services in Europe. More than half of the centers awarded 5 stars in the Eurosafe Wall of Stars, accredited by the European Society of Radiology in Europe, are Affidea centers. In June this year, Affidea was awarded the Diagnostic Provider of the Year Award at the HealthInvestor Awards 2022.